Why Tesla’s Future Hinges on Robotaxis and its Growing Energy Business
Tesla’s robotaxis will have to wildly outperform expectations to offset major shrinkage from Musk’s political exposure.
BTC$61,771.00+3.06%
ETH$1,595.53+4.93%
USDT$0.9996-0.01%
USDC$0.99970.00%
XRP$1.12+6.14%
SOL$63.97+5.48%
TRX$0.3245+1.74%
FIGR_HELOC$1.03+0.46%
HYPE$58.85+1.23%
DOGE$0.0835+6.68%
USDS$0.99970.00%
LEO$9.43-2.03%
RAIN$0.0131+3.94%
XLM$0.2101+10.68%
CC$0.1661+13.29%
BTC$61,771.00+3.06%
ETH$1,595.53+4.93%
USDT$0.9996-0.01%
USDC$0.99970.00%
XRP$1.12+6.14%
SOL$63.97+5.48%
TRX$0.3245+1.74%
FIGR_HELOC$1.03+0.46%
HYPE$58.85+1.23%
DOGE$0.0835+6.68%
USDS$0.99970.00%
LEO$9.43-2.03%
RAIN$0.0131+3.94%
XLM$0.2101+10.68%
CC$0.1661+13.29%
Fiserv shares jumped 5.76% in premarket trading following the announcement of FIUSD, a new stablecoin platform.
Tesla’s robotaxis will have to wildly outperform expectations to offset major shrinkage from Musk’s political exposure.
Accenture's stock tumbled 5.88% on June 20, 2025, despite beating Q3 earnings expectations.
GMS shares soar nearly 20% in premarket trading as Home Depot enters bidding war with QXO over the $5 billion building products distributor.
Oil prices rally to multi-month highs as Middle East war tensions intensify and Trump hints at possible US intervention.
Nike's Q4 earnings on June 26 face major headwinds with guided mid-teens revenue decline.
AI models are still far from robust, which leaves Microsoft with plenty of leeway to deliver automation of mental tasks across its products without OpenAI.
Jabil's stock has surged 42.48% year-to-date, driven by three key factors.
The military industrial complex is getting an AI facelift with these companies at the forefront.
Aptevo Therapeutics stock soared 123% in premarket trading following promising Phase 1b/2 trial results.
JetBlue Airways announces major cost-cutting measures including flight reductions and route eliminations.
Solar stocks crashed following Senate Republicans' proposal to eliminate key tax incentives for renewable energy by 2028.
Eli Lilly is reportedly close to acquiring gene editing partner Verve Therapeutics for up to $1.3 billion.